Bisphosphonates for periprosthetic bone loss after joint arthroplasty: A meta-analysis of 14 randomized controlled trials

Osteoporosis International

Volumn 23, Issue 6, 2012, Pages 1823-1834

  Lin, T ^a   Yan, S G ^a   Cai, X Z ^a   Ying, Z M ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Arthroplasty; Bisphosphonate; Bone mineral density; DEXA; Meta analysis

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; FOLLOW UP; GENETIC HETEROGENEITY; HIP ARTHROPLASTY; HUMAN; KIDNEY FUNCTION; KNEE ARTHROPLASTY; META ANALYSIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; STRESS FRACTURE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863624303     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1797-5     Document Type: Article

References (41)

1. Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, de Vries F, Cooper C, Arden NK (2011) Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum 63:992-1001.
2. Cook RE, Jenkins PJ, Walmsley PJ, Patton JT, Robinson CM (2008) Risk factors for periprosthetic fractures of the hip: a survivorship analysis. Clin Orthop Relat Res 466(7):1652-1656.
3. Purdue PE, Koulouvaris P, Nestor BJ, Sculco TP (2006) The central role of wear debris in periprosthetic osteolysis. HSS J 2:102-113. (Pubitemid 44328104)
4. Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987-99. J Bone Joint Surg Br 83:579-586.
5. Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, Gretzer C (2006) Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop 77:177-197.
6. Brown DL, Robbins R (1999) Developments in the therapeutic applications of bisphosphonates. J Clin Pharmacol 39:651-660.
7. Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, Schunemann H, Einhorn TA (2005) Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am 87:293-301. (Pubitemid 40216626)
8. Laupacis A, Straus S (2007) Systematic reviews: time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med 147:273-274. (Pubitemid 351664584)
9. Fokter SK, Komadina R, Repse-Fokter A (2006) Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wien Klin Wochenschr 118(SUPPL. 2):23-28. (Pubitemid 43989529)
10. Trevisan C, Ortolani S, Romano P, Isaia G, Agnese L, Dallari D, Grappiolo G, Cherubini R, Massari L, Bianchi G (2010) Decreased periprosthetic bone loss in patients treated with clodronate: a 1-year randomized controlled study. Calcif Tissue Int 86:436-446.
11. Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 27:183-188.
12. Shetty N, Hamer AJ, Stockley I, Eastell R, Willkinson JM (2006) Clinical and radiological outcome of total hip replacement 5 years after pamidronate therapy. A trial extension. J Bone Joint Surg Br 88:1309-1315. (Pubitemid 44613145)
13. Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kroger HP (2010) Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty-a 5-year follow-up of 16 patients. Scand J Surg 99:32-37.
14. Wang CJ, Wang JW, Ko JY, Weng LH, Huang CC (2006) Threeyear changes in bone mineral density around the knee after a sixmonth course of oral alendronate following total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Am 88:267-272.
15. Yamaguchi K, Masuhara K, Yamasaki S, Fuji T, Seino Y (2004) Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone 35:217-223. (Pubitemid 38789167)
16. Furlan AD, Pennick V, Bombardier C, van Tulder M (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 34:1929-1941 (Phila Pa 1976).
17. Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490.
18. Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, Chichester, England Hoboken NJ.
19. Arabmotlagh M, Rittmeister M, Hennigs T (2006) Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res 24:1336-1341. (Pubitemid 44083248)
20. Hennigs T, Arabmotlagh M, Schwarz A, Zichner L (2002) Dosedependent prevention of early periprosthetic bone loss by alendronate. Z Orthop Ihre Grenzgeb 140:42-47. (Pubitemid 34214319)
21. Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM (2001) Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 16:2126-2131. (Pubitemid 32995405)
22. Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Chen HS (2003) The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am 85-A:2121-2126.
23. Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R (2005) Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res 23:1-8. (Pubitemid 40045070)
24. Wilkinson JM, Stockley I, Peel NF, Hamer AJ, Elson RA, Barrington NA, Eastell R (2001) Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 16:556-564. (Pubitemid 32173371)
25. Fokter SK, Komadina R, Repse-Fokter A, Yerby SA, Kocijancic A, Marc J (2005) Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty. Int Orthop 29:362-367. (Pubitemid 41712822)
26. Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T (2003) Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone 33:144-149. (Pubitemid 36952696)
27. Yamaguchi K, Masuhara K, Yamasaki S, Fuji T (2005) Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci 10:32-36. (Pubitemid 40193005)
28. Abu-Rajab RB, Watson W, Gallacher P, Walker B, Meek RMD (2009) The effect of 6 months oral alendronate treatment on periprosthetic bone loss after total knee arthroplasty. Eur J Orthop Surg Traumatol 19:231-235.
29. Nishioka T, Yagi S, Mitsuhashi T, Miyamoto M, Tamura T, Kobayashi T, Enishi T (2007) Alendronate inhibits periprosthetic bone loss around uncemented femoral components. J Bone Miner Metab 25:179-183. (Pubitemid 46643763)
30. Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kroger PJ (2002) Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int 71:472-477. (Pubitemid 36935463)
31. Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J (2003) Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study. Rev Chir Orthop Reparatrice Appar Mot 89:593-598. (Pubitemid 37498417)
32. Huang JF, Liu JB (2007) Alendronate prevents early femoral periprosthetic bone loss following total hip arthroplasty. Journal of Jiangsu University 17:542-544 (Medicine Edition).
33. Wang YM, Li X, Wang JQ, Guo SY (2005) Study on the periprosthetic bone loss after cemented primary total hip replacement. Tianjin Medical Journal 33:492-494.
34. Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y (2007) Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int 18:1009-1015. (Pubitemid 46889560)
35. Takeyama S, Shinoda H (2003) Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 13:115-121.
36. Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network metaanalysis. Semin Arthritis Rheum 40:275-284.
37. Uusi-Rasi K, Sievanen H, Heinonen A, Kannus P, Vuori I (2004) Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-month follow-up of a randomized, controlled trial. Bone 35:799-805. (Pubitemid 39141883)
38. Antic VN, Fleisch H, Muhlbauer RC (1996) Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif Tissue Int 58:443-448. (Pubitemid 26162482)
39. Shapses SA, Kendler D, Robson R, Hansen KE, Sherrel R, FieldMP, Woolf E, Berd Y,Mantz AM, Santora A (2011) Effect of alendronate and vitamin D(3) on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. J Bone Miner Res 26:1836-1844.
40. Tanko LB, Mouritzen U, Lehmann HJ et al (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687-693. (Pubitemid 37297391)
41. Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M (2007) Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 23:1341-1349 (Pubitemid 46998443)